Overview

GLP-1 Analogs for Neuroprotection After Cardiac Arrest

Status:
Completed
Trial end date:
2016-06-01
Target enrollment:
Participant gender:
Summary
Experimental studies and previous clinical trials suggest neuroprotective effects of GLP-1 analogs in various degenerative neurological diseases, and in hypoxic brain injuries in experimental designs. This study is designed as a safety and feasibility study with patients randomized 1:1 to receive GLP-1 analogs immediately after hospital admission after out of hospital cardiac arrest.
Phase:
N/A
Details
Lead Sponsor:
Jesper Kjaergaard
Treatments:
Exenatide
Glucagon-Like Peptide 1